Formulary Search
A to Z of Drugs : S
Records returned : 196 (on 29 May 2025 at 00:41:59).
Show Icon and Status Keys
Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Do not co-administer with an ACEi or ARB due to risk of angioedema.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Granules
Restrictions / Comments:
Important
Do not co-administer with an ACEi or ARB due to risk of angioedema.
Only licensed for use in children.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Granules
Restrictions / Comments:
Important
This drug (for this indication) has not yet been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to the APC.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (dry powder)
Restrictions / Comments:
Important
Preferred
Cost-effective, low carbon DPI.
Prescribe by BRAND.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (dry powder)
Restrictions / Comments:
Important
Preferred
Cost-effective, low carbon DPI.
Prescribe by BRAND.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Nebules
Restrictions / Comments:
Important
Specialist recommendation following patient initiation and education on nebuliser therapy, unless for administration as PSD in practice for acute attack.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Nebules
Restrictions / Comments:
Important
Specialist recommendation following patient initiation and education on nebuliser therapy, unless for administration as PSD in practice for acute attack.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Important
Unlicensed use in under 12 years of age.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Modified release tablets
- Oral solution
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (breath actuated Metered Dose)
Restrictions / Comments:
Important
Second line, as an alternative to Salbutamol Easyhaler, in patients needing a breath actuated inhaler
Second line - for patients needing a breath-actuated device
Links :
Indication :
Status :
Formulations :
- Inhaler (breath actuated Metered Dose)
Restrictions / Comments:
Important
Second line, as an alternative to Salbutamol Easyhaler, in patients needing a breath actuated inhaler
Second line - for patients needing a breath-actuated device
Links :
Indication :
Status :
Formulations :
- Inhaler (Metered Dose)
Restrictions / Comments:
Important
No dose counter. Lower carbon footprint than Ventolin Evohaler.
Prescribe by BRAND.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (Metered Dose)
Restrictions / Comments:
Important
No dose counter. Lower carbon footprint than Ventolin Evohaler.
Prescribe by BRAND.
Links :
Indication :
Status :
Formulations :
- Inhaler (dry powder)
Restrictions / Comments:
Important
Preferred
Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.
Not for initiation in new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (dry powder)
Restrictions / Comments:
Important
Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.
Not for initiation in new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (dry powder)
Restrictions / Comments:
Important
Preferred
Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.
Prescribe by BRAND
Links :
Indication :
Status :
Formulations :
- Inhaler (dry powder)
Restrictions / Comments:
Important
Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.
Prescribe by BRAND
Links :
Indication :
Status :
Formulations :
- Inhaler (Metered Dose)
Restrictions / Comments:
Important
No dose counter. Higher carbon footprint than the Salamol MDI.
Not for initiation in new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (Metered Dose)
Restrictions / Comments:
Important
No dose counter. Higher carbon footprint than the Salamol MDI.
Not for initiation in new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Infusion
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (Metered Dose)
Restrictions / Comments:
Important
Serevent Evohaler
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (dry powder)
Restrictions / Comments:
Important
Serevent Accuhaler
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (Metered Dose)
Restrictions / Comments:
Important
Serevent Evohaler
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhaler (dry powder)
Restrictions / Comments:
Important
Serevent Accuhaler
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
Restricted Antimicrobial - requires GUM specialist approval
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
Specialist centres only
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Subcutaneous injection (sc)
Restrictions / Comments:
Important
Severe disease only
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Existing patients would not be expected to change therapy unless appropriate to do so.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Ointment
- Suppositories
Restrictions / Comments:
Important
Preferred
Scheriproct ointment and suppositories are considerably less expensive than Proctosedyl and Anusol HC in primary care.
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
Specialist centres only
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Subcutaneous injection (sc)
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Subcutaneous injection (sc)
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Important
NHSE commissioned services only. No Surrey Heartlands Trusts are commissioned to provide this.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Subcutaneous injection (sc)
Restrictions / Comments:
Important
Dulaglutide is 1st line.
Semaglutide is the 2nd line option for WEEKLY injection. Max of 13 Ozempic pens per patient per year (1 pen is a 4 week supply).
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Oral semaglutide is not a preferred route due to poor availability and gastrointestinal side effects.
Use may be appropriate in a small cohort of patients where injection isn't suitable.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Important
This drug has not yet been assessed for formulary status for the prevention of cardiovascular events. Contact your pharmacy team for advice on making an application to APC.
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Important
Only for the ASPH pilot clinics in young people aged 12 to 16 years.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Pre-filled pen
- Subcutaneous injection (sc)
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Liquid
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Eye drops
Restrictions / Comments:
Important
Specialist ophthalmology use only
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Preferred
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intravenous injection (IV)
Restrictions / Comments:
Important
RSFT ICU consultants only.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
SASH only - under shared care agreement with tertiary centre.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Transfer of prescribing to primary care only after specialist team initiation and supply of at least the first month of treatment.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral suspension
Restrictions / Comments:
Important
Children only
Links :
Indication :
Status :
Formulations :
- Suspension
Restrictions / Comments:
Important
RSCH only - For the breakdown of bubbles to facilitate visualisation during endoscopic procedures.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Liquid
Restrictions / Comments:
Important
Prescribe as 200ml
2nd line High Energy Formula
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
This drug has not yet been assessed for formulary status. Contact your pharmacy team for advice on making an application to APC.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Gel
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
For EXISTING patients: GPs may continue to prescribe for existing post-transplant patients only. NHS England are looking to repatriate these patients in the future. GPs must not accept any new requests to prescribe for new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
For NEW patients: RED drug for post-transplant. Funded by NHS England. GPs should not accept any requests to prescribe post-transplant.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Preferred
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Barrier film foam
Restrictions / Comments:
Important
Foams are least cost-effective. Consider a spray. NOT for repeat prescribing.
MEDI DERMA-S STERILE NON STING MEDICAL BARRIER FILM APPLICATORS
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Barrier film foam
Restrictions / Comments:
Important
Foams are least cost-effective. Consider a spray. NOT for repeat prescribing.
CAVILON FOAM APPLICATORS
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Barrier film foam
Restrictions / Comments:
Important
Foams are least cost-effective. Consider a spray. NOT for repeat prescribing.
Other products are considered 2nd-line if 1st-line options are unsuitable (Independence Fusion Applicators)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Spray
Restrictions / Comments:
Important
Preferred
NOT for repeat prescribing
STOCARE PROTECT SKIN BARRIER SPRAY
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Spray
Restrictions / Comments:
Important
Preferred
NOT for repeat prescribing
SKIN SAFE PROTECTIVE SPRAY
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Spray
Restrictions / Comments:
Important
NOT for repeat prescribing
Other products are considered 2nd-line if 1st-line options are unsuitable (Sorbaderm no sting barrier film spray, Cavilon no sting barrier film pump spray)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Wipes
Restrictions / Comments:
Important
Wipes are less cost-effective. Consider a spray film.
NOT for repeat prescribing
SKIN GEL PROTECTIVE DRESSING WIPES
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Wipes
Restrictions / Comments:
Important
Wipes are less cost-effective. Consider a spray film.
NOT for repeat prescribing
DERMA-GARD SKIN WIPES
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Wipes
Restrictions / Comments:
Important
Wipes are less cost-effective. Consider a spray film.
NOT for repeat prescribing
Other products are considered 2nd-line if 1st-line options are unsuitable (Salts Barrier film wipes, Medi Derma-S non-sting medical barrier film wipes, Cavilon no sting barrier film stoma wipes)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Wipes
Restrictions / Comments:
Important
Wipes are less cost-effective. Consider a spray film.
NOT for repeat prescribing
STOCARE PROTECT BARRIER WIPES
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Liquid
Restrictions / Comments:
Important
Pre -thickened formula should not be prescribed. Available OTC
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Liquid
Restrictions / Comments:
Important
Only in exceptional clinical circumstances as communicated by the specialist, with an expectation to transition to powder) NOT parental convenience. Prescribe as 200ml and review need at each prescription with consideration for transition to powder
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Powder
Restrictions / Comments:
Important
Prescribe 800g tin
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Liquid
Restrictions / Comments:
Important
Preferred
Prescribe as 200ml
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Liquid
Restrictions / Comments:
Important
Lactose Free Formula should not be prescribed. Available OTC
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
Severe disease only
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Important
NHSE specialised commissioned services only. Not commissioned from any acute Trust in Surrey Heartlands.
However, this drug may be used in the emergency treatment of urea cycle disorders in patients on acute admission.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Ear drops
Restrictions / Comments:
Important
5% ear drops. Available to purchase for self care.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intravenous infusion
Restrictions / Comments:
Important
https://www.toxbase.org/
https://www.toxbase.org/
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intravenous infusion
Restrictions / Comments:
Important
https://www.toxbase.org/
https://www.toxbase.org/
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intravenous infusion
Restrictions / Comments:
Important
https://www.toxbase.org/
https://www.toxbase.org/
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Important
https://www.toxbase.org/ . Stock not held by Surrey Trusts. Available from regional centres. Refer to TOXBASE / NPIS for advice
https://www.toxbase.org/
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Links :
Indication :
Status :
Formulations :
- Eye drops
Restrictions / Comments:
Important
5% eye drops for corneal oedema.
Primary Care to prescribe by brand - OptimiseRx will be used to identify the most cost effective brand at the point of prescribing
Links :
Indication :
Status :
Formulations :
- Eye drops (preservative free)
Restrictions / Comments:
Important
5% preservative free eye drops for corneal oedema.
Primary Care to prescribe by brand - OptimiseRx will be used to identify the most cost effective brand at the point of prescribing
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Eye ointment
Restrictions / Comments:
Important
Primary Care to prescribe generically as 5% eye ointment preservative free (Alissa Healthcare) - to ensure licensed, Tariff product is supplied.
Links :
Indication :
Status :
Formulations :
- Irrigation solution
Restrictions / Comments:
Important
0.9% sodium chloride pods, sachets, bags, bottles
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Irrigation solution
Restrictions / Comments:
Important
Balanced Salt Solution
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Irrigation solution
Restrictions / Comments:
Important
Balanced Salt Solution Plus
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhalation
- Nebules
Restrictions / Comments:
Important
0.9% sodium chloride in 2.5ml unit dose ampoules.
OptimiseRx will be used to inform Primary Care prescribers of the locally preferred, cost effective brand.
Primary Care may prescribe on recommendation from the Respiratory Care Team who will ensure that patients have had suitable training and trial of equipment to ensure safe use.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhalation
- Nebules
Restrictions / Comments:
Important
3% hypertonic sodium chloride
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhalation
- Nebules
Restrictions / Comments:
Important
6% hypertonic sodium chloride
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Inhalation
- Nebules
Restrictions / Comments:
Important
7% hypertonic sodium chloride
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Nasal drops
Restrictions / Comments:
Important
0.9 % sodium chloride nasal drops. Can be purchased for self care
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Enema
Restrictions / Comments:
Links :
Indication :
Status :
Formulations :
- Oral solution
Restrictions / Comments:
Important
Prior to emergency caesarian section
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
Hypercalcaemia of malignancy. Bone metastases. Prevention of skeletal events.
Initiation and stabilisation for a minimum of 3 months by specialist team before any request for primary care prescribing.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Hypercalcaemia of malignancy. Bone metastases. Prevention of skeletal events.
Initiation and stabilisation for a minimum of 3 months by specialist team before any request for primary care prescribing.
Links :
Indication :
Status :
Formulations :
- Eye drops
Restrictions / Comments:
Important
Preferred
Sodium cromoglycate 2% or Antazoline with Xylometazoline (Otrivine-Antistin) are the preferred antihistamine/anti-inflammatory eye drops
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
GP initiation on specialist recommendation.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral solution
Restrictions / Comments:
Important
Prescribing for children: Express the dose in terms of elemental iron and iron salt and select the most appropriate preparation; specify both the iron salt and formulation on the prescription.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Infusion
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Eye drops
- Eye drops (preservative free)
Restrictions / Comments:
Important
Moderate dry eye.
Prescribe by brand (primary care)
1st line:
Eyeaze preservative free (0.1%, 0.2%, 0.4%)
VIZhyal preservative free (0.1%, 0.2%, 0.4%)
2nd line:
Hy-Opti 0.2%
Clinitas Multi preservative free (0.2%, 0.4%)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intra-ocular injection
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intravenous injection (IV)
Restrictions / Comments:
Important
https://www.toxbase.org/ . Not a 1st-line treatment option. Consider if alternatives are unavailable.
Stock not held by Surrey Trusts. Available from regional centres. Refer to TOXBASE / NPIS for advice
https://www.toxbase.org/
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intravenous infusion
Restrictions / Comments:
Important
Unlicensed.
Hypertensive crisis
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Granules
- Tablets
Restrictions / Comments:
Important
NHSE specialised commissioned services only. Not commissioned from any acute Trust in Surrey Heartlands.
However, this drug may be used in the emergency treatment of urea cycle disorders in patients on acute admission.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral solution
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (powder)
Restrictions / Comments:
Important
PICOLAX sachets - off-label use. ADULTS only at SASH. Adults and children at RSFT.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (powder)
Restrictions / Comments:
Important
CITRAFLEET - ADULTS only. Off-label use
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral solution
Restrictions / Comments:
Important
Off-label for faecal impaction
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (powder)
Restrictions / Comments:
Important
Off-label for faecal impaction
Picolax sachets.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (powder)
Restrictions / Comments:
Important
Off-label for faecal impaction
Citrafleet sachets. Off-label use.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral solution
Restrictions / Comments:
Important
Off-label for faecal impaction
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (powder)
Restrictions / Comments:
Important
Off-label for faecal impaction
ASPH: 2nd line after macrogol.
RSFT: If Movicol/Laxido disimpaction regimen has been unsuccessful (with/without a stimulant laxative).
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (powder)
Restrictions / Comments:
Important
Picolax sachets. SASH / RSFT = Plenvu (polyethylene glycol) is 1st line.
ASPH = paediatrics only
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (powder)
Restrictions / Comments:
Important
Citrafleet sachets.
RSFT 2nd line if Picolax is unsuitable / unavailable.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (powder)
Restrictions / Comments:
Important
Picolax sachets. Licensed in >1 year of age.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intravenous injection (IV)
Restrictions / Comments:
Important
https://www.toxbase.org/
https://www.toxbase.org/
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Crushable tablets
- Gastro-resistant tablets
- Modified release tablets
- Oral solution
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules (slow release)
- Granules (slow release)
Restrictions / Comments:
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Crushable tablets
- Gastro-resistant tablets
- Modified release tablets
- Oral solution
- Tablets
Restrictions / Comments:
Important
Pregnancy Prevention Programme required. See MHRA advice
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules (slow release)
- Granules (slow release)
Restrictions / Comments:
Important
Pregnancy Prevention Programme required. See MHRA advice
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Important
Pregnancy Prevention Programme required. See MHRA advice
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.
Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Requires approval from HCV national team for use
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Preferred
1st line unless contra-indicated
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral suspension
Restrictions / Comments:
Important
Only for patients with swallowing difficulties.
Prescribe as solifenacin 1mg/ml oral SUSPENSION
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral solution
Restrictions / Comments:
Important
Prescribe as solifenacin 1mg/ml oral SUSPENSION
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
QVH = local sleep specialist centre
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Vials
Restrictions / Comments:
Important
Initiation by diabetes team only
Links :
Indication :
Status :
Formulations :
- Vials
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form.
Links :
Indication :
Status :
Formulations :
- Solution for injection
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Important
This drug has not yet been assessed for formulary status. Contact your pharmacy team for advice on making an application to APC.
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Important
This drug has not yet been assessed for formulary status. Contact your pharmacy team for advice on making an application to APC.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Subcutaneous injection (sc)
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Sotagliflozin is not yet available in the NHS. The NICE TA622 will not be implemented until the product is available. Place in therapy will also be determined at this time.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
Primary care and outpatient prescribing of antivirals for COVID 19 treatment is through the CMDU service
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Infusion
Restrictions / Comments:
Important
This drug has not yet been assessed for formulary status. Contact your pharmacy team for advice on making an application to APC.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral solution
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral solution
- Tablets
Restrictions / Comments:
Important
Preferred
Spironolactone is the preferred aldosterone antagonist for all stages of heart failure.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Step 4 of the hypertension pathway. Adjunct in resistant hypertension
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Important
Composition and further info: https://www.sps.nhs.uk/articles/what-is-st-markos-electrolyte-mix-solution/
Patients are able to make their own rehydration solution in primary care. GPs do not prescribe
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
Restricted Antimicrobial - requires GUM Specialist approval
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (granules)
Restrictions / Comments:
Links :
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
Initiation and adjustment by consultant paediatricians only.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Flange extenders
Restrictions / Comments:
Important
COMFORT FLANGE EXTENDERS (small, large, wide)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Flange extenders
Restrictions / Comments:
Important
SALTS FLANGE EXTENDERS
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Flange extenders
Restrictions / Comments:
Important
DANSAC X-TRA STRIPS BARRIER EXTENDER
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Flange extenders
Restrictions / Comments:
Important
BRAVA ELASTIC TAPE and BRAVA ELASTIC TAPE X-LARGE
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Flange extenders
Restrictions / Comments:
Important
CERAPLUS BARRIER EXTENDER
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Paste
Restrictions / Comments:
Important
Up to two tubes per month only
DANSAC SOFT PASTE
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Paste
Restrictions / Comments:
Important
Up to two tubes per month only
ADAPT PASTE
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Paste
Restrictions / Comments:
Important
Up to two tubes per month only
Other products are considered 2nd-line if 1st-line options are unsuitable (Brava paste, Stomahesive paste)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Paste
Restrictions / Comments:
Important
Up to two tubes per month only
SALTS STOMA PASTE
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Powder
Restrictions / Comments:
Important
Stoma powders are not for primary care prescribing.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Lozenges
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intrapleural injection
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intravenous infusion
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Important
Restricted Antimicrobial - requires Microbiology Specialist Approval.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sachets (granules)
Restrictions / Comments:
Important
Rheumatology only. Reserved for severe osteoporosis in patients for whom other treatment options are not suitable.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
https://www.toxbase.org/ . Stock not held by Surrey Trusts. Available from regional centres. Refer to TOXBASE / NPIS for advice
https://www.toxbase.org/
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral suspension
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Unlicensed product.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Sublingual tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Toxoplasmosis only
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral suspension
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Gastro-resistant tablets
Restrictions / Comments:
Important
Enteric coated tablets are significantly more expensive. Reserve for patients unable to tolerate plain tablets.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Suppositories
Restrictions / Comments:
Links :
Indication :
Status :
Formulations :
- Gastro-resistant tablets
- Oral suspension
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral suspension
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
- Nasal spray
Restrictions / Comments:
Important
Prescribe generically.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
- Nasal spray
- Tablets
Restrictions / Comments:
Important
Preferred
Prescribe generically.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Lotion SPF 50
Restrictions / Comments:
Important
Only approved on the NHS for 2 indications - see PAD
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Lotion SPF 50
Restrictions / Comments:
Important
Only approved on the NHS for 2 indications - see PAD
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
NHS England - specialist centres only
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Eye drops
Restrictions / Comments:
Important
Severe dry eye - patients with Meibomian glandular disease
Prescribe by brand. Prescribe on specialist recommendation
Links :